Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals, live microbial products and vaccines, plus the associated business, from SynCo Bio Luxembourg Sarl.
For Wacker, maintaining SynCo’s existing customer relationships is a top priority. Moreover, Wacker is keeping on SynCo’s employees.
Founded in 2000, SynCo Bio Partners has some 110 employees and operates two fermentation lines with current capacities of 1,500 and 270 litres. These lines manufacture microbial-derived biopharmaceuticals, not only for clinical testing but also for the commercial market. There is a further line of single-use fermenters, which provides additional and flexible production capabilities.
SynCo’s service offering is rounded out with a “fill and finish” facility, which enables the complete manufacture of pharmaceuticals from the active agent to the filled product. The facilities meet GMP quality standards, and they have already been inspected by the European Medicines Agency (EMA) and FDA and approved for the manufacture of specific pharmaceutical proteins.
